Research Article
Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast
Table 4
Baseline characteristics of included PSCC in our institution.
| Characteristics | Number |
| Age (median, range) | 54.5 years (range: 39–80 years) | ER status | Positive | 0 | Negative | 28 (100%) | PR status | Positive | 1 (3.6%) | Negative | 27 (96.4%) | HER-2 status | Positive | 3 (10.7%) | Negative | 25 (89.3%) | Ki-67 status | ≥20% | 26 (92.9%) | <20% | 2 (7.1%) | Tumor size (median, range) | 3 cm (range: 0.5–15 cm) | Adjuvant chemotherapy | Yes | 25 (89.3%) | No | 3 (10.7%) | Adjuvant radiotherapy | Yes | 15 (53.6%) | No | 13 (46.4%) | Types of PSCC | Pure | 12 (42.9) | Mixed | 16 (57.1%) | Tumor stage | T1 | 9 (32.1%) | T2 | 18 (64.3%) | T3 | 0 | T4 | 1 (3.6%) | Nodal status | N0 | 22 (78.6%) | N1 | 5 (17.9%) | N2 | 1 (3.6%) | Treatment | LUMP + RT | 8 (28.6%) | MAST only | 13 (46.4%) | MAST + RT | 7 (25%) |
|
|
MAST, mastectomy; LUMP, lumpectomy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor.
|